Tags : Hologic

Weekly Snapshot

PharmaShots Weekly Snapshots (Feb 08 – 12, 2021)

Visby’s POC COVID-19 Test Receives the US FDA’s EUA for Use in CLIA Waived Settings Published: Feb 12, 2020 | Tags: Visby, POC, COVID-19, Test, Receives, US, FDA, EUA, Use, CLIA, Waived, Settings Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies Published: Feb 12, 2020 | Tags: Takeda, Collaborates, Ensoma, Accelerate, Next-Generation, Vivo Gene […]Read More


Hologic Collaborate with Google Cloud to Advance Screening in Cervical

Shots: The companies collaborated to integrate Google Cloud’s ML technologies with Hologic’s Genius Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe The alliance promises to migrate the system’s data management infrastructure to the cloud, and the two companies will also work to further develop its deep learning […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Jan 4-8, 2020)

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Published: Jan 7, 2020 | Tags: Almirall, Tyris, Collaborate, Develop, Next Generation, Gene Therapies Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD    Published: Jan 7, 2020 | Tags: Sarepta, Reports, Mixed Results, SRP-9001, (rAAVrh74.MHCK7.micro-dystrophin), Part 1, Study 102, […]Read More

M&A MedTech

Hologic to Acquire Biotheranostics for ~$230M

Shots: Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021 The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics […]Read More


Hologic to Acquire Somatex for ~$64 M

Shots: Hologic acquired Somatex Medical Technologies for ~$64M. The acquisition of Somatex’s differentiated products will enable Hologic to strengthen & expand its breast marker portfolio The acquisition allows the company to expand its biopsy portfolio with the improvement in the biopsy experience for their patients. The acquisition provides Hologic additional expertise and capabilities to continue […]Read More

Top 20

Top 20 Diagnostics Companies Based on 2019 Revenue

Diagnostics has emerged as one of the largest and fastest-growing segments with evolving diseases. The segment has played a vital role in diagnosing growing and ageing global population with increasing health expenditure and more prevalent lifestyle ailments including obesity, cancer, and cardiovascular diseases. Our team at PharmaShots has compiled a list of top 20 diagnostics […]Read More

Top 20

Top 20 Diagnostics Companies Based On 2018 Revenue

With the era of growing diseases, Diagnostics have played a vital role in diagnosing multiple diseases and disorders. The healthcare system is changing, with a greater focus on value, reducing errors and giving more cost-effective care and treatments. The Diagnostic ledger has not changed much in comparison to 2017. Roche Diagnostics holds to be at […]Read More


Hologic & Cepheid’s Diagnostic Tests Receive 510(k) Clearance for Extragenital

Shots: The approval follows the clinical study assessing Hologic’s Aptima Combo 2 Assay and Cepheid’s Xpert CT/NG in 2,500+ patients to detect the presence of the bacteria Chlamydia trachomatis and Neisseria gonorrhoeae through diagnostic testing of extragenital specimens The study results demonstrated that Aptima Combo 2 Assay and the Xpert CT/NG for extragenital specimens are […]Read More